SCA
UTHR icon

SAC Capital Advisors’s United Therapeutics UTHR Stock Holding History

SAC Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,497
Closed -$235K – 980
2014
Q1 		$235K Sell
2,497
-21,677
-90% -$2.22M ﹤0.01% 1508
2013
Q4 		$2.73M Buy
+24,174
New +$2.18M 0.02% 626

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

SAC Capital Advisors's UTHR Position: Q2 2014 in Review

SAC Capital Advisors sold out of United Therapeutics (UTHR) in Q2 2014, closing a stake of 2,497 shares — an estimated $235K sold.

SAC Capital Advisors first reported a position in UTHR in Q4 2013 and held it in 2 quarters. The position peaked at $2.73M in Q4 2013. 303 funds tracked by Wall St. Rank hold UTHR as of Q2 2014.

  • SAC Capital Advisors reported no remaining United Therapeutics position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 2,497 United Therapeutics shares in Q2 2014, an estimated $235K.
  • SAC Capital Advisors first reported a position in United Therapeutics in Q4 2013 and held it in 2 quarters.
  • SAC Capital Advisors's United Therapeutics position peaked at $2.73M in Q4 2013.
  • 303 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.